← Product Code [FGB](/productcode/FGB) · K262437

# Single-use Digital Flexible Ureteroscope (GY-UR6.3); Single-use Digital Flexible Ureteroscope (GY-UR6.3A) (K262437)

_Zhejiang Geyi Medical Instrument Co., Ltd. · FGB · Oct 29, 2026 · Gastroenterology, Urology · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K262437

## Device Facts

- **Applicant:** Zhejiang Geyi Medical Instrument Co., Ltd.
- **Product Code:** [FGB](/productcode/FGB.md)
- **Decision Date:** Oct 29, 2026
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 876.1500
- **Device Class:** Class 2
- **Review Panel:** Gastroenterology, Urology
- **Attributes:** Therapeutic

## Indications for Use

Single-use Digital Flexible Ureteroscope is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.

## Device Story

Single-use digital flexible ureteroscope; used for transurethral visualization of urinary tract; includes insertion tube, deflection section, CMOS image sensor, LED light source, and working channel. Operates with external endoscope camera system (portable processor/generator); CMOS sensor captures tissue images; LED provides illumination; control lever enables 275° deflection. Used by clinicians in clinical settings. Output displayed on connected host system; assists in diagnostic/therapeutic procedures (e.g., stone removal via basket, laser fiber use). Benefits include single-use sterility, reducing cross-contamination risk.

## Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing including mechanical performance (deflection, tensile, torque, fatigue), image quality (FOV, resolution, SNR, etc.), shelf-life (ASTM F1980-21), and electrical/EMC safety (IEC 60601 series).

## Technological Characteristics

Flexible ureteroscope; single-use; EO sterilized. Features: 160,000 pixel CMOS sensor, LED illumination, 275° active deflection, 650mm working length, 1.0mm working channel. Connectivity: electrical connection to external camera processor. Standards: IEC 60601-1, IEC 60601-2-18, IEC 60601-1-2, ASTM F1980-21.

## Regulatory Identification

An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.

## Special Controls

*Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.

In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls:

1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following:
   1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures.
   2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use.
   3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use.
2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes.
3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches
4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error.
5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program.
(6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms.
(7) Labeling must include:
(i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified;
(ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA;
(iii) Identification of compatible devices;
(iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification;
(v) Reprocessing instructions for reusable components;
(vi) A shelf life for any sterile components;
(vii) A description of the device-specific use training program;
(viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and
(ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance.
(8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include:
(i) Device motion accuracy and repeatability;
(ii) System testing;
(iii) Instrument reliability;
(iv) Crosstalk;
(v) Table motion control;
(vi) Thermal effects on tissue;
(vii) User-device interface performance;
(viii) Workspace access testing; and
(ix) Performance testing with compatible devices.
(9) Software verification, validation, and hazard analysis must be performed.
(10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed.
(11) Performance data must demonstrate the sterility of all patient-contacting device components.
(12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life.
(13) Performance data must validate the reprocessing instructions for the reusable components of the device.
(14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible.
(15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic.
(16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information:
(i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and
(ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period.

## Predicate Devices

- single-use Digital Flexible Ureteroscope ([K252468](/device/K252468.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{1}

[LOGO]

FDA

U.S. FOOD & DRUG

ADMINISTRATION

October 29, 2026

Zhejiang Geyi Medical Instrument Co., Ltd.

Cathy Tan

# 1, 2 Factory, # 5, Hutang Rd. Xiaya Town

Jiande City, Zhejiang 311606

CHINA

Re: K262437

Trade/Device Name: Single-use Digital Flexible Ureteroscope (GY-UR6.3);
Single-use Digital Flexible Ureteroscope (GY-UR6.3A)

Regulation Number: 21 CFR 876.1500

Regulation Name: Endoscope and accessories

Regulatory Class: II

Product Code: FGB

Dated: October 7, 2026

Received: October 8, 2026

Dear Cathy Tan:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: The Center for Devices and Radiological Health (CDRH) does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, the Food and Drug Administratio (FDA) may publish further announcements concerning your device in the Federal Register.

Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that

U.S. Food & Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993

www.fda.gov

{2}

K262437 - Cathy Tan

Page 2

may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See

{3}

K262437 - Cathy Tan

Page 3

the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Mark R. Kreitz -S

for Mark J. Antonino, M.S.

Assistant Director

DHT3B: Division of Reproductive,

Gynecology, and Urology Devices

OHT3: Office of Gastrorenal, ObGyn,

General Hospital, and Urology Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

{4}

|  Indications for Use  |   |   |
| --- | --- | --- |
|  Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K262437 | ?  |
|  Please provide the device trade name(s). |   | ?  |
|  Single-use Digital Flexible Ureteroscope (GY-UR6.3); Single-use Digital Flexible Ureteroscope (GY-UR6.3A)  |   |   |
|  Please provide your Indications for Use below. |   | ?  |
|  Single-use Digital Flexible Ureteroscope is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.  |   |   |
|  Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ?  |
|  Please select the age group(s) for which the device(s) is to be used. | ☐ Neonates/Newborns (Birth to < 29 days old) ☐ Infants (29 days old to < 2 years old) ☐ Children (2 years old to < 12 years old) ☐ Adolescents (12 years old to < 22 years old) ☐ Adults (22 years old and greater) | ?  |

{5}

K262437, Page 1 of 3

|  510(k) #: K262437 | 510(k) Summary | Prepared on: 2026-10-08  |
| --- | --- | --- |
|  Contact Details |   | 21 CFR 807.92(a)(1)  |
|  Applicant Name | Zhejiang Geyi Medical Instrument Co.,Ltd.  |   |
|  Applicant Address | No. 1, 2 Factory, No. 5, Hutang Road Xiaya Town Jiande City Zhejiang 311606 China  |   |
|  Applicant Contact Telephone | +86 15158157854  |   |
|  Applicant Contact | Ms. Cathy Tan  |   |
|  Applicant Contact Email | lilyxu@zjgeyi.com  |   |
|  Device Name |   | 21 CFR 807.92(a)(2)  |
|  Device Trade Name | Single-use Digital Flexible Ureteroscope (GY-UR6.3); Single-use Digital Flexible Ureteroscope (GY-UR6.3A)  |   |
|  Common Name | Endoscope and accessories  |   |
|  Classification Name | Ureteroscope And Accessories, Flexible/Rigid  |   |
|  Regulation Number | 876.1500  |   |
|  Product Code(s) | FGB  |   |
|  Legally Marketed Predicate Devices |   | 21 CFR 807.92(a)(3)  |
|  Predicate # | Predicate Trade Name (Primary Predicate is listed first) | Product Code  |
|  K252468 | single-use Digital Flexible Ureteroscope | FGB  |
|  Device Description Summary |   | 21 CFR 807.92(a)(4)  |
|  The Single-Use Digital Flexible Ureteroscope system consists of Single-Use Digital Flexible Ureteroscope and Endoscope camera system. The Single-Use Digital Flexible Ureteroscope consists of an insertion part, an operating part, and an electrical connection part. The insertion part includes the distal tip, deflection section, insertion tube, CMOS module, LED light source, and the opening of the working channel. The tip is integrated with LED lighting source, 160,000 pixel CMOS image sensor and instrument channel tube with inner diameter of 1.0mm. During use, LED light source provides illumination, CMOS image sensor is used to collect image pixels of tissue parts, and instrument channel tube is used as the use channel of stone basket, holmium laser fiber, etc. Under the upper and lower 45° swing operation of the control lever, the upper and lower 275° swing Angle of the deflection section can be realized. The operation department is equipped with two functional shortcut keys, which have corresponding functions preset with the endoscope camera host. Press the key and the host will have corresponding functions. The Single-Use Digital Flexible Ureteroscope is powered by the Endoscope camera system. The electrical connection department transmits the image pixels obtained by the image sensor to the host, thus realizing the function of surgical imaging. The Endoscopic Camera System receives a video signal from a connected endoscope, controls the light from the tip of the endoscope and outputs that signal, including a graphical user interface, while presenting the image to the user. Endoscope camera system consists of a portable image processor generator, Power flexible cable (1.5m) x1, Power adapter (cable 1.0m)x1, HDMI cable (2.0m)x1. The Single-Use Digital Flexible Ureteroscope is provided sterile (sterilized by EO) and intended to be single-use. The Endoscope camera system is a reusable multi-patient use device.  |   |   |
|  Intended Use/Indications for Use |   | 21 CFR 807.92(a)(5)  |

{6}

K262437, Page 2 of 3

Single-use Digital Flexible Ureteroscope is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.

## Indications for Use Comparison

21 CFR 807.92(a)(5)

The indications for use are the same as K252468.

## Technological Comparison

21 CFR 807.92(a)(6)

The device has the same product code, regulation number, indications for use, design, material, principle of operation, scope type (flexible), scope re-usability (single use), sterilization method (EO), illumination source (LED), active deflection in both directions (275°), working length(650mm), Field of View(120°), direction of view (0°), Depth of Field(3-50mm), resolution (160,000 pixels)as the predicate device(s).

The proposed device is available in 2 models with maximum insertion widths of 2.4 mm, and minimum instrument channel widths of 1.0 mm, and the predicate device has maximum insertion widths of 3.2 mm, 3.0mm and 2.8 mm and minimum instrument channel widths of 1.2 mm and 1.0mm, respectively, which are smaller in maximum insertion widths and in minimum instrument channel widths compared to the predicate device. The proposed device utilizes CMOS (TA10), which differs from the CMOS (6946) incorporated in the predicate device. All the performance of proposed device was tested and the results met the standard requirements, this difference will not raise any issues in safety and effectiveness of the device.

## Non-Clinical and/or Clinical Tests Summary & Conclusions

21 CFR 807.92(b)

The following performance testing was conducted using previously submitted methods and acceptance criteria cleared under K252468 in support of the substantial equivalence, as shown in the table below.

The mechanical performance include following items:

☑Surface and edges

☑Maximum insert section width

☑Minimum Working channel width

☑Working length

☑Flow rate of water

☑Leak

☑Control lever

☑Maneuverability of surgical instruments in a bent state

☑Angle of deflection

Tensile testing

☑Torque testing

☑Fatigue testing

Comparative testing related to image quality parameters including following list was performed for proposed device and the predicate device to support substantial equivalence.:

☑Color performance

☑Field of view (FOV)

☑Direction of view (DOV)

☑Uniformity

☑Depth of field (DOF)

☑Resolution

☑Distortion

☑Signal-to-noise ratio (SNR)

☑Dynamic range

Shelf Life

Shelf life is determined based on stability study which includes ageing test according to ASTM F1980-21 Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices

Electrical safety and electromagnetic compatibility (EMC)

Electrical Safety and EMC data include in the submission meet the following standards.

☑EC 60601-1:2012, and AAMI/ANSI ES60601-1:2005/(R)2012 And A1:2012, C1:2009/(R)2012 And A2:2010/(R)2012

☑EC 60601-2-18:2009: Part 2-18

☑EC 60601-1-2:2014 and A1:2020

{7}

K262437, Page 3 of 3

SEC TS 60601-4-2: 2024

AIM7351731 Rev.3.0

ANSI C63.18:2014

Based on the intended use/indications for use, comparison of key technological characteristics, and performance testing presented in this premarket notification demonstrated that the proposed is substantially equivalent to the currently marketed predicate device and can be safely and effectively used for its proposed indications.

---

**Source:** [https://fda.innolitics.com/device/K262437](https://fda.innolitics.com/device/K262437)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com
